ライフサイエンスコーパス: cancer research

1 ation of differentially methylated genes for cancer research.

2 , which are molecules of growing interest in cancer research.

3 nships and affected the direction of gastric cancer research.

4 t, significant efforts are being invested in cancer research.

5 on, and the Garron Family Chair in Childhood Cancer Research.

6 re at The Royal Marsden and the Institute of Cancer Research.

7 dscape of phosphoinositide signaling axis in cancer research.

8 onary tool that has been used extensively in cancer research.

9 ic modifications are an attractive target in cancer research.

10 in tumour progression is at the forefront of cancer research.

11 ic levels, and discuss their applications in cancer research.

12 reducing side effects, is a primary goal of cancer research.

13 acy is critical for modern multidisciplinary cancer research.

14 h tool that plays an ever-increasing role in cancer research.

15 re, or truly represents a paradigm shift for cancer research.

16 d array of current translational products in cancer research.

17 cimens are a valuable resource for molecular cancer research.

18 overcome, would significantly contribute to cancer research.

19 ies hold great potential for applications in cancer research.

20 orms is an active area of both chemistry and cancer research.

21 common practice in clinical diagnostics and cancer research.

22 nce these data toward mainstream adoption in cancer research.

23 velopment, tissue mosaicism, immunology, and cancer research.

24 ry, developmental biology, neuroscience, and cancer research.

25 ncer cells, yet have been largely ignored in cancer research.

26 le models for basic and translational breast cancer research.

27 prediction is a well-known problem in breast cancer research.

28 edictive value of animal-based translational cancer research.

29 generate preclinical murine models for liver cancer research.

30 s such, they have put PLD at center stage in cancer research.

31 esents one of the 'Provocative Questions' in cancer research.

32 cancer metastasis are two major problems in cancer research.

33 Nanotechnology is widely used in cancer research.

34 etic systems with potential applications for cancer research.

35 nce reproducibility and drive innovations in cancer research.

36 iagnostics, the Nuovo-Soldati foundation for cancer research.

37 Lebanese-Syrian Associated Charities, Swiss Cancer Research.

38 ant implications for basic and translational cancer research.

39 o develop a powerful analytical platform for cancer research.

40 MicroRNAs (miRNAs) hold great promise in cancer research.

41 abolism and represents a useful paradigm for cancer research.

42 rsden NHS Foundation Trust, and Institute of Cancer Research.

43 s, which are increasingly required in modern cancer research.

44 sociated with commercializing academic-based cancer research.

45 s is one of the most pressing needs in basic cancer research.

46 xicity to normal tissues are a major goal in cancer research.

47 rgence of resistance is a major challenge in cancer research.

48 omic developers addressing critical needs in cancer research.

49 pathways has been placed in the forefront of cancer research.

50 ifferent areas, namely leukemia and melanoma cancer research.

51 immune evasion and the future prospects for cancer research.

52 or improving reproducibility in pre-clinical cancer research.

53 tal benchmark for immunogenomics analyses in cancer research.

54 m FA research serves basic and translational cancer research.

55 evelopmental biology as well as stem cell or cancer research.

56 ification has long been an important task in cancer research.

57 ly facilitate application of NGS in clinical cancer research.

58 iew, knowledge discovery and applications in cancer research.

59 of cancer have become highly influential in cancer research.

60 en tumors and normal tissue is a mainstay of cancer research.

61 stage II-III patients remains challenging in cancer research.

62 s into clinically relevant model systems for cancer research.

63 ical validation for similar methods in human cancer research.

64 ificant contributions to the field of kidney cancer research.

65 l Research Network, Swiss Group for Clinical Cancer Research.

66 ain oncogenic states, remains a challenge in cancer research.

67 gy and its potential in supporting practical cancer research.

68 at are widely deployed in preclinical breast cancer research.

69 lighted as one of the important topics among cancer researches.

70 form of vitamin D, has been applied in anti-cancer researches.

71 in this Cancer Research section, "Physics in Cancer Research."

72 et al., Cancer Res 1994;54:1169-74Visit the Cancer Research 75(th) Anniversary timeline.

73 et al., Cancer Res 1987;47:3239-45Visit the Cancer Research 75(th) Anniversary timeline.

74 et al., Cancer Res 1999;59:2615-22Visit the Cancer Research 75(th) Anniversary timeline.

75 et al., Cancer Res 1986;46:5629-32Visit the Cancer Research 75(th) Anniversary timeline.

76 The American Association for Cancer Research (AACR) and the American Society of Clini

77 Subcommittee of the American Association for Cancer Research (AACR) Science Policy and Government Aff

78 h Fund (WCRF) and the American Institute for Cancer Research (AICR) is associated with reduced all-ca

79 In this issue of Cancer Research, Almassalha and colleagues have proposed

80 d significant examples of systems applied in cancer research, also discussing those that take a multi

82 study indicate the applicability of FETs for cancer research and analyzing pharmacological effects of

83 increased recognition as important tools in cancer research and anticancer drug development.

84 In the past 2 years, lung cancer research and clinical care have advanced signific

85 ns, which will likely have utility in breast cancer research and clinical practice.

86 rs that can be targeted for CTC isolation in cancer research and diagnosis.

87 nd measurement of circulating tumor cells in cancer research and disease management.

88 toacoustic imaging being propagated to basic cancer research and in clinical translation projects.

89 w spans many of the most active paradigms in cancer research and includes agents that target cancer-r

90 d to facilitate the selection of strains for cancer research and is a platform for mining data on tum

91 y by invitation and consent in both Clinical Cancer Research and Journal of Clinical Oncology.

92 xplored applications that still lie ahead in cancer research and medicine.

93 Advances in cancer research and personalized medicine will require s

94 ort researchers generating new hypotheses in cancer research and personalized medicine.

95 riendly web interface designed to facilitate cancer research and personalized medicine.

96 providing nearly US$2 billion of funding for cancer research and precision medicine.

97 extends across many fields, from evo-devo to cancer research and regenerative medicine.

98 re of the meeting, a coalition of pancreatic cancer research and support foundations participated, wi

99 n permission by the American Association for Cancer Research and the American Society of Clinical Onc

100 on, which would provide new perspectives for cancer research and therapeutics.

101 ce, and a long-term commitment to supporting cancer research and training.

102 n Ministry of Health, Italian Association of Cancer Research, and Biodesix.

103 Methods ASCO, Friends of Cancer Research, and the US Food and Drug Administration

104 d application of HM models, their promise in cancer research, and their potential in generating clini

105 -16S2); Intramural Program of the Center for Cancer Research; and the Division of Cancer Treatment an

106 isease, and here, we especially focus on its cancer research applications.

107 Verification that cell lines used for cancer research are derived from malignant cells in prim

108 This highly cited 1999 Cancer Research article from Adams and colleagues was pu

109 Imaging has steadily evolved in clinical cancer research as a result of improved conventional ima

110 nerated significant interest in the field of cancer research as a therapeutic target for many metasta

111 diet and human cancer has a long history in cancer research, as has interest in the mechanisms by wh

112 In cancer research, as in all of medicine, it is important

113 "two-hit model." This is highly relevant for cancer research, as mitochondrial metabolism holds a cen

114 ers would enhance the use of mouse models in cancer research, as well as for other diseases.

115 In cancer research, background models for mutation rates ha

116 The focus of pancreatic cancer research began to change with the identification

117 ntre and The Royal Marsden and Institute for Cancer Research Biomedical Research Centre and is coordi

118 combinase technology are important tools for cancer research but can be costly and time-consuming.

119 ewer and more sophisticated mouse models for cancer research, but we believe that, without an appreci

120 ncer are mimicked in basic and translational cancer research by a steadily increasing number of tumor

121 network-oriented communities of interest in cancer research by adapting methods from academic publis

122 early 1900s, the landmark article in 1978 in Cancer Research by Dougherty and his colleagues at the R

123 estone of this effort was the publication in Cancer Research by Wynder and colleagues, which demonstr

124 rostate Cancer Canada, Ontario Institute for Cancer Research, Canadian Institute for Health Research,

125 tion process utilized at the Fred Hutchinson Cancer Research Center (Seattle, Washington) by the coor

126 nclusive at our institution (Fred Hutchinson Cancer Research Center) into this phase 1 trial.

127 1 of 4 well-defined cohorts (Fred Hutchinson Cancer Research Center, Haemato Oncology Foundation for

128 e included patients from the Fred Hutchinson Cancer Research Center, WA, USA, who received an allogen

129 entre, open-label, phase 1b trial done at 13 cancer research centres in the USA, Israel, Japan, South

130 In cancer research, colony formation assay is a gold standa

131 via a study of the barriers associated with cancer research commercialization at the University of K

132 1) What are the general barriers inhibiting cancer research commercialization at UK? and 2) Would mi

133 American Society of Clinical Oncology (ASCO) Cancer Research Committee to these historical cases.

134 The American Society of Clinical Oncology Cancer Research Committee, which comprises academic facu

135 lable resource for the digital pathology and cancer research communities.

136 ears, and three challenges to the pancreatic cancer research community as it moves toward to the goal

137 ligner will be an important resource for the cancer research community by providing detailed clues fo

138 ts support DNF as a valuable resource to the cancer research community by providing new hypotheses on

139 The cancer research community is increasingly embracing this

140 SGene), has become a popular resource in the cancer research community.

141 and maintained as a useful resource for the cancer research community.

142 dance of biological networks relevant to the cancer research community; (ii) provide a medium for col

143 cancer enrolled in the Translational Breast Cancer Research Consortium (TBCRC) 013.

144 Human liver cancer research currently lacks in vitro models that can

145 serve as an invaluable supplemental tool in cancer research, diagnostics, drug efficacy assessment,

146 Those who have participated in cancer research during this period have witnessed wild f

147 l investment in the remarkably productive US cancer research enterprise.

148 Methods ASCO and Friends of Cancer Research established a multidisciplinary working

149 of Gloria Heppner and how it has influenced cancer research even three decades after it was publishe

150 Institute, Frederick National Laboratory for Cancer Research, Federal Funds from National Institute o

151 erapies is an important issue facing current cancer research field.

152 ll detection which have a huge potential for cancer research for medical or biomedicine applications.

153 anta, GA, USA), Swiss Re (London, UK), Swiss Cancer Research foundation (Bern, Switzerland), Swiss Ca

154 ses, National Cancer Institute, Damon Runyon Cancer Research Foundation Clinical Investigator Award,

155 (Malcolm Broomhead Bequest), the Australian Cancer Research Foundation, and the Cancer Council of Qu

156 alia, Victorian Cancer Agency, Samuel Waxman Cancer Research Foundation, the Health and Science Depar

157 F Hoffmann-La Roche-Genentech and the Breast Cancer Research Foundation.

158 state policy makers in India have championed cancer research, from studies to achieve low-tech, large

159 ncer prevention recommendations of the World Cancer Research Fund (WCRF) and the American Institute f

160 Research Program, Stand Up To Cancer-Ovarian Cancer Research Fund Alliance-National Ovarian Cancer Co

161 In 2007 the World Cancer Research Fund and American Institute for Cancer R

162 World Cancer Research Fund International, European Commission

163 tion of Plastic Surgeons, the Meirion Thomas Cancer Research Fund, and the National Institute for Hea

164 d Medical Research Council Australia, Breast Cancer Research Fund, AstraZeneca, Sanofi Aventis.

165 isation for Research and Treatment of Cancer Cancer Research Fund.

166 In cancer research, genomic data from cell lines are often

167 Japan Agency for Medical Research; and Swiss Cancer Research grant.

168 sting an increasing influence of industry on cancer research, greater disclosure, or both.

169 L who were treated in consecutive ECOG-ACRIN Cancer Research Group frontline clinical trials in an at

170 merican College of Radiology Imaging Network Cancer Research Group trial E1900 (#NCT00049517) showed

171 Dutch Cancer Society (CKTO), Dutch Lung Cancer Research Group, Cancer Research UK, Manchester Ac

172 ECOG-ACRIN Cancer Research Group, National Cancer Institute of the

173 US National Cancer Institute and ECOG-ACRIN Cancer Research Group, Pfizer, and Bayer.

174 Although extensive cancer research has been conducted utilizing animal mode

175 Cancer research has been rightly and successfully focuse

176 A major goal of pediatric cancer research has been to identify key drivers of tumo

177 longstanding investment in federally funded cancer research has contributed significantly to a growi

178 intratumor heterogeneity, much attention in cancer research has focused on profiling heterogeneity o

179 Cancer research has long been hampered by the limitation

180 Growing participation by industry in cancer research has resulted in increased reporting of c

181 ned by an acute problem: Federal funding for cancer research has steadily eroded over the past decade

182 Recent advances in glycobiology and cancer research have defined the key processes underlyin

183 Recent advances in bladder cancer research have enhanced our understanding of the o

184 Past decades of cancer research have mainly focused on the role of vario

185 A widely accepted paradigm in cancer research holds that the development of cancers is

186 was developed in 1985-1986 and published in Cancer Research in 1987.

187 European Network for Cancer Research in Children and Adolescents, funded thro

188 Over the past 20 years, cancer research in India has grown in size and impact.

189 Cancer research in India is a complex environment that n

190 nfectious disease monitoring, immunology and cancer research in the future.

191 hese areas are critical focal points for HPV cancer research in the next decade.

192 As part of the UK National Cancer Research Institute (NCRI) AML17 trial, 1206 adult

193 HOVON], UK Medical Research Council/National Cancer Research Institute [MRC/NCRI], and the US coopera

194 ndergone intensive treatment in the National Cancer Research Institute AML17 trial.

195 myeloma and were enrolled onto the National Cancer Research Institute Myeloma XI trial, for whom com

196 thwest Oncology Group (SWOG) and UK National Cancer Research Institute/Medical Research Council (NCRI

197 ing, concluding with implications for moving cancer research into the clinic.

198 normous potential of immunotherapies against cancer, research into the interactions between tumor and

199 he importance of evaluating physical cues in cancer research is gradually being realized.

200 earch on other types of solid tumors, breast cancer research is hampered by a lack of tractable in vi

201 vitro, engineered surrogates in the field of cancer research is of interest for studies involving mec

202 A major goal of cancer research is the identification of tumor-specific

203 A major goal in translational cancer research is to identify biological signatures dri

204 eath, and despite all the recent advances in cancer research it is still mostly incurable.

205 alth Research, Association for International Cancer Research, Jason Boas Fellowship, Imperial Biomedi

206 entations given at the Irish Association for Cancer Research Meeting and importantly how the results

207 Despite current advances in cancer research, metastasis remains the leading factor i

208 r intravenous cannulation, male Institute of Cancer Research mice were randomized to chow (n = 11) or

209 r venous cannulation, male ICR (Institute of Cancer Research) mice were randomized to receive chow (n

210 In the January 1, 2017, issue of Cancer Research, Nagel and colleagues demonstrate the va

211 son strategy that addresses a central aim of cancer research, namely cancer driver-passenger distinct

212 hould prove relevant in other fields such as cancer research, nanotoxicity, and energy storage and pr

213 The TIES Cancer Research Network now provides integrated access t

214 Kidney Cancer SPORE P50 CA101942-01, Kidney Cancer Research Network of Canada, Canadian Institute fo

215 The TIES Cancer Research Network presents a model for a national

216 he Text Information Extraction System (TIES) Cancer Research Network, a federated network that facili

217 for Health Research through the UK National Cancer Research Network, the Medical Research Council, a

218 d the National Institute for Health Research Cancer Research Network.

219 d the National Institute for Health Research Cancer Research Network.

220 rials Coordination Unit, and the UK National Cancer Research Network.

221 With the fast growth of cancer research, new analytical methods are needed to me

222 e planned work, and the expected benefits to cancer research, patient and provider decision making, c

223 s Oncology, US Department of Defense Ovarian Cancer Research Program, Stand Up To Cancer-Ovarian Canc

224 Foundation, US Department of Defense Breast Cancer Research Program, Susan G Komen for the Cure, Bre

225 Cancer research relies heavily on murine models for eval

226 ectively utilizing digital pathology data in cancer research requires the ability to manage, visualiz

227 K hospitals and one Swiss Group for Clinical Cancer Research (SAKK) hospital.

228 and Human Services, Swiss Group for Clinical Cancer Research (SAKK), Frontier Science and Technology

229 See all articles in this Cancer Research section,

230 See all articles in this Cancer Research section, "Physics in Cancer Research."

231 is important in areas including physiology, cancer research, stem-cell differentiation and drug disc

232 Despite this, most in vitro cancer research still relies primarily on cells grown in

233 cations presented in this article is used in cancer research studies of morphologic characteristics o

234 M can facilitate biomarker-driven integrated cancer research that can lead to a detailed understandin

235 ions is an important and challenging area of cancer research that can provide new insights into gene

236 Worldwide Cancer Research, The Big C, UK National Institutes for H

237 In cancer research, the comparison of gene expression or DN

238 e of the greatest advances in the history of cancer research: the development of vaccines that preven

239 In cancer research, this strategy has been particularly suc

240 approach is impacting many diverse areas of cancer research, through review of the key presentations

241 studies of the hypoxia pathway in pancreatic cancer research to date have focused on fully malignant

242 d its matched normal has been widely used in cancer research to distinguish germline polymorphisms fr

243 ression profiling is being widely applied in cancer research to identify biomarkers for clinical endp

244 convened in May 2016 by ASCO and Friends of Cancer Research to identify opportunities for when it wo

245 gorithms have begun to see widespread use in cancer research to reconstruct processes of evolution in

246 l can be readily adopted in cell biology and cancer research to uncover, to our knowledge, novel driv

247 t that for innovations derived from academic cancer-research to move more effectively and efficiently

248 Clinical cancer research today often includes testing the value o

249 take an honest appraisal about the state of cancer research today, to debate "currently entrenched v

250 Cancer Research UK (C569/A5032), National Health and Med

251 rch Cancer Network, following endorsement by Cancer Research UK (CRUKE/04/022).

252 stitute New South Wales (Sydney, Australia), Cancer Research UK (London, UK), Centers for Disease Con

253 Cancer Research UK (UK) and the National Health and Medi

254 Cancer Research UK and Chief Scientist Office of the Sco

255 Cancer Research UK and National Health Service (NHS) fun

256 Cancer Research UK and the Royal College of Obstetrician

257 Randomisation was centralised through the Cancer Research UK and University College London Cancer

258 Randomisation was done by Cancer Research UK Clinical Trials Unit staff with a min

259 Academy of Medical Sciences Starter Grant, Cancer Research UK New Agents Committee Grant.

260 Cancer Research UK, Academy of Medical Sciences, Health

261 Jean Mitchell Green Foundation, AstraZeneca, Cancer Research UK, and the National Institute for Healt

262 e Kroner Fresenius Stiftung, Wellcome Trust, Cancer Research UK, AstraZeneca UK, University Hospitals

263 esearch Centre, The University of Cambridge, Cancer Research UK, Cambridge Cancer Charity, Prostate C

264 Medical Research Council, Cancer Research UK, Canadian Cancer Society Research Ins

265 Cancer Research UK, Department of Health, and the Nation

266 Cancer Research UK, Department of Health, and the Nation

267 Medical Research Council, Cancer Research UK, Department of Health, The Eve Appeal

268 Cancer Research UK, Eli Lilly, Bristol-Myers Squibb.

269 Cancer Research UK, EORTC Charitable Trust, UK NHS, Cana

270 Biomedical Research Centres funding scheme, Cancer Research UK, EPSRC Multidisciplinary Assessment o

271 Research Council, British Heart Foundation, Cancer Research UK, European Union, WHO International Ag

272 Cancer Research UK, Janssen-Cilag, and Chugai Pharma UK.

273 Cancer Research UK, Lymphoma Research Trust, Lymphoma As

274 ty (CKTO), Dutch Lung Cancer Research Group, Cancer Research UK, Manchester Academic Health Science C

275 Cancer Research UK, Medical Research Council Clinical Tr

276 man Federal State of North Rhine-Westphalia, Cancer Research UK, Medical Research Council, Commonweal

277 Cancer Research UK, Medical Research Council, Novartis,

278 Dutch Cancer Society, Cancer Research UK, National Health and Medical Research

279 Cancer Research UK, National Health and Medical Research

280 Chugai Pharmaceutical, Cancer Research UK, National Institute for Health Resear

281 coma Group, Swiss Paediatric Oncology Group, Cancer Research UK, National Institute for Health Resear

282 Cancer Research UK, National Institute for Health Resear

283 Cancer Research UK, North Thames National Health Service

284 Associazione Italiana del Farmaco, Cancer Research UK, Oncosuisse, and Swiss National Found

285 Cancer Research UK, Royal College of Surgeons of England

286 Cancer Research UK, the National Health and Medical Rese

287 received from the Medical Research Council, Cancer Research UK, the UK Department of Health, and the

288 Cancer Research UK, Yorkshire Cancer Research, UK Medica

289 UK Medical Research Council, Cancer Research UK.

290 utes of Health, UK Medical Research Council, Cancer Research UK.

291 Cancer Research UK, Yorkshire Cancer Research, UK Medical Research Council, Wellcome T

292 In this issue of Cancer Research, Vivian and colleagues utilize a unique

293 l Conference of the American Association for Cancer Research, was held in Orlando, FL, on May 12 to 1

294 cer Research Fund and American Institute for Cancer Research (WCRF/AICR) report judged that the evide

295 In this issue of Cancer Research, we highlight a paper published by Georg

296 s have attempted to specialize hydrogels for cancer research; we comprehensively review this topic fo

297 ) have historically been at the forefront of cancer research, where they are known to act as critical

298 nomics has emerged as a valuable approach in cancer research, which integrates genomic and transcript

299 Several renowned examples in the history of cancer research will be used to illustrate how modeling

300 Preclinical cancer research would benefit from noninvasive imaging m